{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease (AD)", "fluorescence quenching", "machine learning", "molecular docking", "monoamine oxidase B (MAO-B) inhibitors"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36291679", "DateCompleted": {"Year": "2022", "Month": "10", "Day": "28"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "22"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "10", "Day": "13"}], "Language": ["eng"], "ELocationID": ["1470", "10.3390/biom12101470"], "Journal": {"ISSN": "2218-273X", "JournalIssue": {"Volume": "12", "Issue": "10", "PubDate": {"Year": "2022", "Month": "Oct", "Day": "13"}}, "Title": "Biomolecules", "ISOAbbreviation": "Biomolecules"}, "ArticleTitle": "Discovery of MAO-B Inhibitor with Machine Learning, Topomer CoMFA, Molecular Docking and Multi-Spectroscopy Approaches.", "Abstract": {"AbstractText": ["Alzheimer's disease (AD) is the most common type of dementia and is a serious disruption to normal life. Monoamine oxidase-B (MAO-B) is an important target for the treatment of AD. In this study, machine learning approaches were applied to investigate the identification model of MAO-B inhibitors. The results showed that the identification model for MAO-B inhibitors with\u3000K-nearest neighbor(KNN) algorithm had a prediction accuracy of 94.1% and 88.0% for the 10-fold cross-validation test and the independent test set, respectively. Secondly, a quantitative activity prediction model for MAO-B was investigated with the Topomer CoMFA model. Two separate cutting mode approaches were used to predict the activity of MAO-B inhibitors. The results showed that the cut model with q<sup>2</sup> = 0.612 (cross-validated correlation coefficient) and r<sup>2</sup> = 0.824 (non-cross-validated correlation coefficient) were determined for the training and test sets, respectively. In addition, molecular docking was employed to analyze the interaction between MAO-B and inhibitors. Finally, based on our proposed prediction model, 1-(4-hydroxyphenyl)-3-(2,4,6-trimethoxyphenyl)propan-1-one (LB) was predicted as a potential MAO-B inhibitor and was validated by a multi-spectroscopic approach including fluorescence spectra and ultraviolet spectrophotometry."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Life Science, Shanghai University, Shanghai 200444, China."}, {"Identifier": [], "Affiliation": "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China."}], "LastName": "Zheng", "ForeName": "Linfeng", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, School of Pharmacy, Air Force Medical University, Xi'an 710032, China."}], "LastName": "Qin", "ForeName": "Xiangyang", "Initials": "X"}, {"Identifier": ["0000-0001-9875-5425"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Life Science, Shanghai University, Shanghai 200444, China."}], "LastName": "Wang", "ForeName": "Jiao", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Life Science, Shanghai University, Shanghai 200444, China."}], "LastName": "Zhang", "ForeName": "Mengying", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Clinical Science, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai 200444, China."}], "LastName": "An", "ForeName": "Quanlin", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Clinical Science, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai 200444, China."}], "LastName": "Xu", "ForeName": "Jinzhi", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Engineering Laboratory of Southwest Endangered Medicinal Resources Development, Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China."}], "LastName": "Qu", "ForeName": "Xiaosheng", "Initials": "X"}, {"Identifier": ["0000-0003-1722-023X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Clinical Science, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai 200444, China."}], "LastName": "Cao", "ForeName": "Xin", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Life Science, Shanghai University, Shanghai 200444, China."}], "LastName": "Niu", "ForeName": "Bing", "Initials": "B"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Biomolecules", "NlmUniqueID": "101596414", "ISSNLinking": "2218-273X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Monoamine Oxidase Inhibitors"}, {"RegistryNumber": "EC 1.4.3.4", "NameOfSubstance": "Monoamine Oxidase"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Monoamine Oxidase Inhibitors"}, {"QualifierName": ["chemistry"], "DescriptorName": "Monoamine Oxidase"}, {"QualifierName": [], "DescriptorName": "Spectrum Analysis"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": [], "DescriptorName": "Machine Learning"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Long C.O., Dougherty J. What\u2019s new in Alzheimer\u2019s disease? Home Healthc Nurse. 2003:8\u201314. doi: 10.1097/00004045-200301000-00002.", "ArticleIdList": ["10.1097/00004045-200301000-00002", "12544456"]}, {"Citation": "Harris M.E., Hensley K., Butterfield D.A., Leedle R.A., Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer\u2019s beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 1995;131:193\u2013202. doi: 10.1016/0014-4886(95)90041-1.", "ArticleIdList": ["10.1016/0014-4886(95)90041-1", "7895820"]}, {"Citation": "Luo J., W\u00e4rml\u00e4nder S.K.T.S., Gr\u00e4slund A., Abrahams J.P. Cross-interactions between the Alzheimer Disease Amyloid-\u03b2 Peptide and Other Amyloid Proteins: A Further Aspect of the Amyloid Cascade Hypothesis. J. Biol. Chem. 2016;291:16485\u201316493. doi: 10.1074/jbc.R116.714576.", "ArticleIdList": ["10.1074/jbc.R116.714576", "PMC4974365", "27325705"]}, {"Citation": "Fotiou D., Kaltsatou A., Tsiptsios D., Nakou M. Evaluation of the cholinergic hypothesis in Alzheimer\u2019s disease with neuropsychological methods. Aging Clin. Exp. Res. 2015;27:727\u2013733. doi: 10.1007/s40520-015-0321-8.", "ArticleIdList": ["10.1007/s40520-015-0321-8", "25749905"]}, {"Citation": "Piotr L., Hermann E., Mirko B., Georg B., Manuel M.J., Markus O., Johannes K., Jens W. Tau Protein Phosphorylated at Threonine 181 in CSF as a Neurochemical Biomarker in Alzheimer\u2019s Disease: Original Data and Review of the Literature. J. Mol. Neurosci. 2004;23:115\u2013122.", "ArticleIdList": ["15126697"]}, {"Citation": "Ohta Y., Darwish M., Hishikawa N., Yamashita T., Sato K., Takemoto M., Abe K. Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer\u2019s disease. Geriatr. Gerontol. Int. 2017;17:1843\u20131848. doi: 10.1111/ggi.12971.", "ArticleIdList": ["10.1111/ggi.12971", "28060449"]}, {"Citation": "Greig N.H., Sambamurti K., Lahiri D.K., Becker R.E. Amyloid-\u03b2 precursor protein synthesis inhibitors for Alzheimer\u2019s disease treatment. Ann. Neurol. 2014;76:629. doi: 10.1002/ana.24254.", "ArticleIdList": ["10.1002/ana.24254", "PMC5179032", "25146731"]}, {"Citation": "Rafii M.S. Targeting tau protein in Alzheimer\u2019s disease. Lancet. 2016;388:2842\u20132844. doi: 10.1016/S0140-6736(16)32107-9.", "ArticleIdList": ["10.1016/S0140-6736(16)32107-9", "27863808"]}, {"Citation": "Sasidharan R., Manju S.L., U\u00e7ar G., Baysal I., Mathew B. Identification of Indole-Based Chalcones: Discovery of a Potent, Selective, and Reversible Class of MAO-B Inhibitors. Arch. Der Pharm. 2016;349:627\u2013637. doi: 10.1002/ardp.201600088.", "ArticleIdList": ["10.1002/ardp.201600088", "27373997"]}, {"Citation": "Kumar V., Chadha N., Tiwari A.K., Sehgal N., Mishra A.K. Prospective atom-based 3D-QSAR model prediction, pharmacophore generation, and molecular docking study of carbamate derivatives as dual inhibitors of AChE and MAO-B for Alzheimer\u2019s disease. Med. Chem. Res. 2014;23:1114\u20131122. doi: 10.1007/s00044-013-0704-3.", "ArticleIdList": ["10.1007/s00044-013-0704-3"]}, {"Citation": "Riederer P., Lachenmayer L., Laux G. Clinical Applications of MAO-Inhibitors. Curr. Med. Chem. 2004;11:2033\u20132043.", "ArticleIdList": ["15279566"]}, {"Citation": "Schedin-Weiss S., Inoue M., Hromadkova L., Teranishi Y., Yamamoto N.G., Wiehager B., Bogdanovic N., Winblad B., Sandebring-Matton A., Frykman S., et al. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with gamma-secretase and regulates neuronal amyloid beta-peptide levels. Alzheimers Res. Ther. 2017;9:57. doi: 10.1186/s13195-017-0279-1.", "ArticleIdList": ["10.1186/s13195-017-0279-1", "PMC5540560", "28764767"]}, {"Citation": "Jo S., Yarishkin O., Hwang Y.J., Chun Y.E., Park M., Woo D.H., Bae J.H., Kim T., Lee J., Chun H., et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer\u2019s disease. Nat. Med. 2014;20:886\u2013896. doi: 10.1038/nm.3639.", "ArticleIdList": ["10.1038/nm.3639", "PMC8385452", "24973918"]}, {"Citation": "Xie S., Chen J., Li X., Su T., Wang Y., Wang Z., Huang L., Li X. Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer\u2019s disease. Bioorg. Med. Chem. 2015;23:3722\u20133729. doi: 10.1016/j.bmc.2015.04.009.", "ArticleIdList": ["10.1016/j.bmc.2015.04.009", "25934229"]}, {"Citation": "Lawlor B.A., Aisen P.S., Green C., Fine E., Schme\u00efdler J. Selegiline in the treatment of behavioural disturbance in Alzheimer\u2019s disease. Int. J. Geriatr. Psychiatry. 1997;12:319\u2013322. doi: 10.1002/(SICI)1099-1166(199703)12:3<319::AID-GPS488>3.0.CO;2-Q.", "ArticleIdList": ["10.1002/(SICI)1099-1166(199703)12:3<319::AID-GPS488>3.0.CO;2-Q", "9152715"]}, {"Citation": "Weinreb O., Mandel S., Bar-Am O., Yogev-Falach M., Avramovich-Tirosh Y., Amit T., Youdim M.B.H. Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer\u2019s disease drugs. Neurotherapeutics. 2009;6:163\u2013174. doi: 10.1016/j.nurt.2008.10.030.", "ArticleIdList": ["10.1016/j.nurt.2008.10.030", "PMC5084264", "19110207"]}, {"Citation": "Abdelhafez O.M., Amin K.M., Ali H.I., Abdalla M.M., Batran R.Z. Monoamine oxidase A and B inhibiting effect and molecular modeling of some synthesized coumarin derivatives. Neurochem. Int. 2013;62:198\u2013209. doi: 10.1016/j.neuint.2012.11.005.", "ArticleIdList": ["10.1016/j.neuint.2012.11.005", "23182697"]}, {"Citation": "Jayaprakash V., Sinha B.N., Ucar G., Ercan A. Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorganic Med. Chem. Lett. 2008;18:6362\u20136368. doi: 10.1016/j.bmcl.2008.10.084.", "ArticleIdList": ["10.1016/j.bmcl.2008.10.084", "18980841"]}, {"Citation": "Wang L., Esteban G., Ojima M., Bautistaaguilera O.M., Inokuchi T., Moraleda I., Iriepa I., Samadi A., Youdim M.B., Romero A. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer\u2019s disease. Eur. J. Med. Chem. 2014;80:543\u2013561. doi: 10.1016/j.ejmech.2014.04.078.", "ArticleIdList": ["10.1016/j.ejmech.2014.04.078", "24813882"]}, {"Citation": "Pisani L., Farina R., Nicolotti O., Gadaleta D., Soto-Otero R., Catto M., Di B.M., Mendez-Alvarez E., Carotti A. In silico design of novel 2H-chromen-2-one derivatives as potent and selective MAO-B inhibitors. Eur. J. Med. Chem. 2015;89:98. doi: 10.1016/j.ejmech.2014.10.029.", "ArticleIdList": ["10.1016/j.ejmech.2014.10.029", "25462230"]}, {"Citation": "Cramer R.D. Topomer CoMFA: A design methodology for rapid lead optimization. J. Med. Chem. 2003;46:374\u2013388. doi: 10.1021/jm020194o.", "ArticleIdList": ["10.1021/jm020194o", "12540237"]}, {"Citation": "Zhang C., Ding H., He M., Liu L., Liu L., Li G., Niu B., Zhong X. Comparison of Early Changes in Ocular Surface and Inflammatory Mediators between Femtosecond Lenticule Extraction and Small-Incision Lenticule Extraction. PLoS ONE. 2016;11:e0149503. doi: 10.1371/journal.pone.0149503.", "ArticleIdList": ["10.1371/journal.pone.0149503", "PMC4777367", "26937680"]}, {"Citation": "Hong-jin T., Lin Y., Jia-huang L., Jun C. Molecular modelling studies of 3,5-dipyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors using 3D-QSAR, Topomer CoMFA, molecular docking and molecular dynamic simulations. J. Taiwan Inst. Chem. Eng. 2016;68:64\u201373."}, {"Citation": "Joshi S.D., More U.A., Aminabhavi T.M., Badiger A.M. Two- and three-dimensional QSAR studies on a set of antimycobacterial pyrroles: CoMFA, Topomer CoMFA, and HQSAR. Med. Chem. Res. 2013;23:107\u2013126. doi: 10.1007/s00044-013-0607-3.", "ArticleIdList": ["10.1007/s00044-013-0607-3"]}, {"Citation": "Nilewar S.S., Kathiravan M.K. 3D CoMFA, CoMSIA, topomer CoMFA and HQSAR studies on aromatic acid esters for carbonic anhydrase inhibitory activity. J. Chemom. 2014;28:60\u201370. doi: 10.1002/cem.2574.", "ArticleIdList": ["10.1002/cem.2574"]}, {"Citation": "Jain A.N. Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine. J. Med. Chem. 2003;46:499\u2013511. doi: 10.1021/jm020406h.", "ArticleIdList": ["10.1021/jm020406h", "12570372"]}, {"Citation": "Binda C., Newton-Vinson P., Hub\u00e1lek F., Edmondson D.E., Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 2002;9:22\u201326. doi: 10.1038/nsb732.", "ArticleIdList": ["10.1038/nsb732", "11753429"]}, {"Citation": "Irwin J.J. Software Review:ChemOffice 2005 Pro by CambridgeSoft. J. Chem. Inf. Model. 2005;45:1468\u20131469. doi: 10.1021/ci050286x.", "ArticleIdList": ["10.1021/ci050286x"]}, {"Citation": "Matos M.J., Ter\u00e1n C., P\u00e9rez-Castillo Y., Uriarte E., Santana L., Via D. Synthesis and Study of a Series of 3-Arylcoumarins as Potent and Selective Monoamine Oxidase B Inhibitors. J. Med. Chem. 2011;54:7127\u20137137. doi: 10.1021/jm200716y.", "ArticleIdList": ["10.1021/jm200716y", "21923181"]}, {"Citation": "Bourassa P., Dubeau S., Maharvi G.M., Fauq A.H., Thomas T.J., Tajmir-Riahi H.A. Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin. Biochimie. 2011;93:1089\u20131101.", "ArticleIdList": ["21439346"]}, {"Citation": "Mohammadi F., Bordbar A.-K., Divsalar A., Mohammadi K., Saboury A.A. Interaction of Curcumin and Diacetylcurcumin with the Lipocalin Member \u03b2-Lactoglobulin. Protein J. 2009;28:117\u2013123. doi: 10.1007/s10930-009-9171-6.", "ArticleIdList": ["10.1007/s10930-009-9171-6", "19189206"]}, {"Citation": "Lakowicz J.R., Masters B.R. Principles of Fluorescence Spectroscopy, Third Edition. J. Biomed. Opt. 2008;13:029901. doi: 10.1117/1.2904580.", "ArticleIdList": ["10.1117/1.2904580"]}, {"Citation": "Xie M.-X., Xu X.-Y., Wang Y.-D. Interaction between hesperetin and human serum albumin revealed by spectroscopic methods. Biochim. Et Biophys. Acta Gen. Subj. 2005;1724:215\u2013224. doi: 10.1016/j.bbagen.2005.04.009.", "ArticleIdList": ["10.1016/j.bbagen.2005.04.009", "15923087"]}, {"Citation": "Bi S., Song D., Tian Y., Zhou X., Liu Z., Zhang H. Molecular spectroscopic study on the interaction of tetracyclines with serum albumins. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2005;61:629\u2013636. doi: 10.1016/j.saa.2004.05.028.", "ArticleIdList": ["10.1016/j.saa.2004.05.028", "15649793"]}, {"Citation": "Kandagal P.B., Ashoka S., Seetharamappa J., Shaikh S.M.T., Jadegoud Y., Ijare O.B. Study of the interaction of an anticancer drug with human and bovine serum albumin: Spectroscopic approach. J. Pharm. Biomed. Anal. 2006;41:393\u2013399. doi: 10.1016/j.jpba.2005.11.037.", "ArticleIdList": ["10.1016/j.jpba.2005.11.037", "16413740"]}, {"Citation": "Edmondson D.E., Binda C., Mattevi A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys. 2007;464:269\u2013276. doi: 10.1016/j.abb.2007.05.006.", "ArticleIdList": ["10.1016/j.abb.2007.05.006", "PMC1993809", "17573034"]}, {"Citation": "Heidari A., Fatemi M. CoMFA, topomer CoMFA and HQSAR studies on a series of novel HIV-1 protease inhibitors. Chem. Biol. Drug Des. 2016", "ArticleIdList": ["27933723"]}, {"Citation": "Yang X., Albijanic B., Zhou Y., Zhou Y., Zhu X. Using 3D-QSAR to predict the separation efficiencies of flotation collectors: Implications for rational design of non-polar side chains. Miner. Eng. 2018;129:112\u2013119. doi: 10.1016/j.mineng.2018.09.026.", "ArticleIdList": ["10.1016/j.mineng.2018.09.026"]}, {"Citation": "Kristam R., Rao S.N., D\u2019Cruz A.S., Mahadevan V., Viswanadhan V.N. TRPV1 antagonism by piperazinyl-aryl compounds: A Topomer-CoMFA study and its use in virtual screening for identification of novel antagonists. J. Mol. Graph. Model. 2017;72:112\u2013128. doi: 10.1016/j.jmgm.2017.01.010.", "ArticleIdList": ["10.1016/j.jmgm.2017.01.010", "28092830"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "8", "Day": "15"}, {"Year": "2022", "Month": "9", "Day": "20"}, {"Year": "2022", "Month": "9", "Day": "28"}, {"Year": "2022", "Month": "10", "Day": "27", "Hour": "1", "Minute": "13"}, {"Year": "2022", "Month": "10", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "10", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "10", "Day": "13"}], "PublicationStatus": "epublish", "ArticleIdList": ["36291679", "PMC9599443", "10.3390/biom12101470", "biom12101470"]}}], "PubmedBookArticle": []}